GGTDTC, a copper prochelator of dithiocarbamate was developed to release dithiocarbamate (DTC) in cancer expressing gamma-glutamyl transferase enzyme. Upon release DTC is free to bind to Cu to form toxic Cu(DTC)2 . GGTDTC was found to selectively release diethyldithiocarbamate only in prostate cancer cells with measurable gamma-glutamyl transferase activity. These findings underscore a new strategy to leverage the amplified copper metabolism of prostate cancer by conditional activation of a metal‐binding pharmacophore. Learn more about the Franz lab's recent work in Angewandte Chemie, available here.